Novo Nordisk (NVO) will invest 6.4 billion reais ($1.09 billion) to expand its manufacturing capacity in Brazil, Reuters reported Monday, citing CEO Lars Fruergaard Jorgensen.
The investment will support increased production of treatments for obesity, diabetes, and other chronic diseases at the company's facility in Minas Gerais. Construction is underway on a new 74,000-square-meter facility in Montes Claros, with operations expected to begin in 2028.
The site will produce various formulations, including GLP-1 drugs such as semaglutide, the active ingredient in Ozempic and Wegovy.
Patent expiration is not seen as a major issue, according to Reinaldo Costa, corporate vice president of the Montes Claros facility. The company is also expanding a separate manufacturing site in the US, which does not source products from Brazil, according to the news outlet.
Novo Nordisk did not immediately respond to a request for comment from MT Newswires.
(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。